CoChat
Sign Up
Cited by 22

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

New Therapies to Correct the Cystic Fibrosis Basic Defect

Bergeron, Christelle, Cantin, André M.·2021·International Journal of Molecular Sciences
DOI 10.3390/ijms22126193PMC PMC8227161
Open this paper in CoChat — free account

Abstract

Rare diseases affect 400 million individuals worldwide and cause significant morbidity and mortality. Finding solutions for rare diseases can be very challenging for physicians and researchers. Cystic fibrosis (CF), a genetic, autosomal recessive, multisystemic, life-limiting disease does not escape this sad reality. Despite phenomenal progress in our understanding of this disease, treatment remains difficult. Until recently, therapies for CF individuals were focused on symptom management. The discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and its product, a protein present at the apical surface of epithelial cells regulating ion transport, allowed the scientific community to learn about the basic defect in CF and to study potential therapies targeting the dysfunctional protein. In the past few years, promising therapies with the goal to restore CFTR function became available and changed the lives of several CF patients. These medications, called CFTR modulators, aim to correct, potentialize, stabilize or amplify CFTR function. Furthermore, research is ongoing to develop other targeted therapies that could be more efficient and benefit a larger proportion of the CF community. The purpose of this review is to summarize our current knowledge of CF genetics and therapies restoring CFTR function, particularly CFTR modulators and gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22126193

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Role of the CFTR in the regulation of mucus viscosity and pH at the epithelial surface. Healthy mucus is composed primarily of mucins and water. Hydration and pH regulate mucus viscosity, and both of these functions are controlled by CFTR at the apical surface of epithelial cells. The movement of chloride dictates the degree to which mucus retains water whereas CFTR-mediated bicarbonate flux plays a key role in defining pH which is critical to healthy anti-bacterial response. In the absence of CFTR, secretions are viscous, adhere to mucosal surface and obstruct cylindrical structures such as small airways and sub-mucosal glands. The acidic pH further contributes to decrease host anti-bacterial defenses.
Figure 1 Role of the CFTR in the regulation of mucus viscosity and pH at the epithelial surface. Healthy mucus is composed primarily of mucins and water. Hydration and pH regulate mucus viscosity, and both of these functions are controlled by CFTR at the apical surface of epithelial cells. The movement of chloride dictates the degree to which mucus retains water whereas CFTR-mediated bicarbonate flux plays a key role in defining pH which is critical to healthy anti-bacterial response. In the absence of CFTR, secretions are viscous, adhere to mucosal surface and obstruct cylindrical structures such as small airways and sub-mucosal glands. The acidic pH further contributes to decrease host anti-bacterial defenses.CC BY · PubMed Central
Figure 2 Classification of the CFTR disease-causing mutations. Classes I–III comprise most of the mutations associated with classical CF disease. Examples of alleles of each class are listed for each mutation class. * Class 1A is often referred to as class VII as originally suggested by De Boeck and Amaral [6].
Figure 2 Classification of the CFTR disease-causing mutations. Classes I–III comprise most of the mutations associated with classical CF disease. Examples of alleles of each class are listed for each mutation class. * Class 1A is often referred to as class VII as originally suggested by De Boeck and Amaral [6].CC BY · PubMed Central
Figure 3 Pharmacological strategies for restoring CFTR function in CF individuals with various classes of CFTR mutations. Illustrated in green are agents that increase the open probability of CFTR (potentiators), facilitate escape of misfolded protein from ERAD (correctors of class I act on NBD1, class II on NDBII and class III have an additive corrector effect in the presence of class I corrector), increase the amount of CFTR mRNA (amplifiers), increase proper translation of mRNA with PTC mutations (read-through agents), decrease NMD (NMD suppressor) and prevent degradation of CFTR protein inserted in the plasma membrane (stabilizers).
Figure 3 Pharmacological strategies for restoring CFTR function in CF individuals with various classes of CFTR mutations. Illustrated in green are agents that increase the open probability of CFTR (potentiators), facilitate escape of misfolded protein from ERAD (correctors of class I act on NBD1, class II on NDBII and class III have an additive corrector effect in the presence of class I corrector), increase the amount of CFTR mRNA (amplifiers), increase proper translation of mRNA with PTC mutations (read-through agents), decrease NMD (NMD suppressor) and prevent degradation of CFTR protein inserted in the plasma membrane (stabilizers).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 143

  1. Collins, 2019, Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis, N. Engl. J. Med., 381, 1863, 10.1056/NEJMe1911602 · DOI
  2. Bergeron, 2019, Cystic Fibrosis: Pathophysiology of Lung Disease, Semin. Respir. Crit. Care Med., 40, 715, 10.1055/s-0039-1694021 · DOI
  3. Bardin, 2021, Modulators of CFTR. Updates on clinical development and future directions, Eur. J. Med. Chem., 213, 113195, 10.1016/j.ejmech.2021.113195 · DOI
  4. Somayaji, 2020, Cystic fibrosis—Ten promising therapeutic approaches in the current era of care, Expert Opin. Investig. Drugs, 29, 1107, 10.1080/13543784.2020.1805733 · DOI · Paper page
  5. Amaral, 2016, Progress in therapies for cystic fibrosis, Lancet Respir. Med., 4, 662, 10.1016/S2213-2600(16)00023-0 · DOI
  6. Wilschanski, 1995, Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations, J. Pediatr., 127, 705, 10.1016/S0022-3476(95)70157-5 · DOI
  7. Stanke, 2016, Classification of CFTR mutation classes, Lancet Respir. Med., 4, e36, 10.1016/S2213-2600(16)30147-3 · DOI
  8. Sugarman, 2004, CFTR mutation distribution among U.S. Hispanic and African American individuals: Evaluation in cystic fibrosis patient and carrier screening populations, Genet. Med., 6, 392, 10.1097/01.GIM.0000139503.22088.66 · DOI
  9. Koch, 2001, Ercf Investigators of the. European Epidemiologic Registry of Cystic Fibrosis (Ercf): Comparison of Major Disease Manifestations between Patients with Different Classes of Mutations, Pediatr. Pulmonol., 31, 1, 10.1002/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T · DOI
  10. Veit, 2016, From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations, Mol. Biol. Cell, 27, 424, 10.1091/mbc.e14-04-0935 · DOI
  11. Linde, 2007, Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin, J. Clin. Investig., 117, 683, 10.1172/JCI28523 · DOI
  12. Clarke, 2018, The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: A basis for read-through therapies in cystic fibrosis, Hum. Mutat., 40, 326
  13. Estabrooks, S., and Brodsky, J.L. (2020). Regulation of Cftr Biogenesis by the Proteostatic Network and Pharmacological Modulators. Int. J. Mol. Sci., 21. · DOI
  14. Anderson, 1992, Regulation by Atp and Adp of Cftr Chloride Channels That Contain Mutant Nucleotide-Binding Domains, Science, 257, 1701, 10.1126/science.1382316 · DOI
  15. Accurso, 2010, Effect of Vx-770 in Persons with Cystic Fibrosis and the G551d-Cftr Mutation, N. Engl. J. Med., 363, 1991, 10.1056/NEJMoa0909825 · DOI
  16. Sheppard, 1993, Mutations in Cftr Associated with Mild-Disease-Form Cl- Channels with Altered Pore Properties, Nature, 362, 160, 10.1038/362160a0 · DOI
  17. Moss, 2015, Efficacy and Safety of Ivacaftor in Patients with Cystic Fibrosis Who Have an Arg117his-Cftr Mutation: A Double-Blind, Randomised Controlled Trial, Lancet Respir. Med., 3, 524, 10.1016/S2213-2600(15)00201-5 · DOI
  18. Chu, 1993, Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA, Nat. Genet., 3, 151, 10.1038/ng0293-151 · DOI
  19. Shteinberg, 2017, Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His, ERJ Open Res., 3, 00056, 10.1183/23120541.00056-2016 · DOI
  20. Haardt, 1999, C-terminal Truncations Destabilize the Cystic Fibrosis Transmembrane Conductance Regulator without Impairing Its Biogenesis, J. Biol. Chem., 274, 21873, 10.1074/jbc.274.31.21873 · DOI
  21. Silvis, 2003, A Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Generates a Novel Internalization Sequence and Enhances Endocytic Rates, J. Biol. Chem., 278, 11554, 10.1074/jbc.M212843200 · DOI
  22. Flume, 2012, Ivacaftor in Subjects with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation, Chest, 142, 718, 10.1378/chest.11-2672 · DOI · Paper page
  23. Davies, 2013, Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551d Mutation, Am. J. Respir Crit. Care Med., 187, 1219, 10.1164/rccm.201301-0153OC · DOI
  24. Rowe, 2014, Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis, Am. J. Respir. Crit. Care Med., 190, 175, 10.1164/rccm.201404-0703OC · DOI · Paper page
  25. Hisert, 2017, Restoring Cftr Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections, Am. J. Respir. Crit. Care Med., 195, 1617, 10.1164/rccm.201609-1954OC · DOI
  26. Heltshe, 2015, Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor, Clin. Infect. Dis., 60, 703, 10.1093/cid/ciu944 · DOI
  27. Frost, 2019, Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data, Ann. Am. Thorac. Soc., 16, 1375, 10.1513/AnnalsATS.201902-122OC · DOI
  28. Guimbellot, 2021, Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation, J. Cyst. Fibros., 20, 213, 10.1016/j.jcf.2020.11.008 · DOI
  29. Einarsson, G.G., Ronan, N.J., Mooney, D., McGettigan, C., Mullane, D., NiChroinin, M., Shanahan, F., Murphy, D.M., McCarthy, M., and McCarthy, Y. (2021). Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. J. Cyst. Fibros. · DOI
  30. Volkova, 2020, Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries, J. Cyst. Fibros., 19, 68, 10.1016/j.jcf.2019.05.015 · DOI · Paper page
  31. Kirwan, 2019, Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland, Ann. Am. Thorac. Soc., 16, 209, 10.1513/AnnalsATS.201802-149OC · DOI · Paper page
  32. Hebestreit, 2013, Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation, J. Cyst. Fibros., 12, 599, 10.1016/j.jcf.2013.05.006 · DOI
  33. Barry, 2014, Effects of Ivacaftor in Patients with Cystic Fibrosis Who Carry the G551d Mutation and Have Severe Lung Disease, Chest, 146, 152, 10.1378/chest.13-2397 · DOI
  34. Niknian, 2016, Effect of Ivacaftor in Patients with Advanced Cystic Fibrosis and a G551d-Cftr Mutation: Safety and Efficacy in an Expanded Access Program in the United States, J. Cyst. Fibros., 15, 116, 10.1016/j.jcf.2015.01.008 · DOI
  35. Horsley, 2007, A Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis, Thorax, 63, 135, 10.1136/thx.2007.082628 · DOI
  36. Ratjen, 2018, Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial, Am. J. Respir. Crit. Care Med., 198, 526, 10.1164/rccm.201802-0243LE · DOI
  37. Hoare, 2014, Ivacaftor Imaging Response in Cystic Fibrosis, Am. J. Respir. Crit. Care Med., 189, 484, 10.1164/rccm.201308-1433IM · DOI
  38. Sheikh, 2015, Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation, J. Cyst. Fibros., 14, 84, 10.1016/j.jcf.2014.06.011 · DOI
  39. Chassagnon, 2016, Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor, Eur. Respir. J., 48, 249, 10.1183/13993003.01918-2015 · DOI
  40. Hayes, 2014, Improvement of sinus disease in cystic fibrosis with ivacaftor therapy, Am. J. Respir. Crit. Care Med., 190, 468, 10.1164/rccm.201403-0595IM · DOI
  41. Davies, 2016, Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study, Lancet Respir. Med., 4, 107, 10.1016/S2213-2600(15)00545-7 · DOI
  42. Smith, 2020, Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor, Pediatr. Pulmonol., 55, 2493, 10.1002/ppul.24952 · DOI
  43. Megalaa, 2019, Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use, Pediatr. Pulmonol., 54, E16, 10.1002/ppul.24353 · DOI
  44. Nichols, 2020, Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor, Paediatr. Respir. Rev., 35, 99
  45. Munce, 2020, Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor, Pediatr. Pulmonol., 55, 3381, 10.1002/ppul.25065 · DOI
  46. Kounis, 2018, Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis, Am. J. Gastroenterol., 113, 1058, 10.1038/s41395-018-0123-7 · DOI
  47. Watson, 2020, The Association of Pediatric Cystic Fibrosis-Related Diabetes Screening on Clinical Outcomes by Center: A Cf Patient Registry Study, J. Cyst. Fibros, 19, 316, 10.1016/j.jcf.2019.07.010 · DOI · Paper page
  48. Prinz, 2020, Glucose Tolerance in Patients with Cystic Fibrosis—Results from the German Cystic Fibrosis Registry, Klin. Padiatr., 232, 210, 10.1055/a-1117-3771 · DOI
  49. Bellin, 2013, Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: A small pilot study, Pediatr. Diabetes, 14, 417, 10.1111/pedi.12026 · DOI
  50. Hayes, 2014, Resolution of Cystic Fibrosis–related Diabetes with Ivacaftor Therapy, Am. J. Respir. Crit. Care Med., 190, 590, 10.1164/rccm.201405-0882LE · DOI
  51. Gaines, 2021, Effect of Cftr Modulator Therapy on Cystic Fibrosis-Related Diabetes, J. Diabetes Complicat., 35, 107845, 10.1016/j.jdiacomp.2020.107845 · DOI
  52. Salvatore, 2020, Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function, Respir. Med., 171, 106073, 10.1016/j.rmed.2020.106073 · DOI
  53. Rosenfeld, 2019, An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB), J. Cyst. Fibros., 18, 838, 10.1016/j.jcf.2019.03.009 · DOI
  54. Trimble, 2018, Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation, J. Cyst. Fibros., 17, e13, 10.1016/j.jcf.2017.09.006 · DOI
  55. Veit, 2020, Mutation-specific dual potentiators maximize rescue of CFTR gating mutants, J. Cyst. Fibros., 19, 236, 10.1016/j.jcf.2019.10.011 · DOI
  56. Durmowicz, 2018, The U.S. Food and Drug Administration’s Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial, Ann. Am. Thorac. Soc., 15, 1, 10.1513/AnnalsATS.201708-668PS · DOI
  57. Rowe, 2010, Deltaf508 Cftr Processing Correction and Activity in Polarized Airway and Non-Airway Cell Monolayers, Pulm. Pharmacol. Ther., 23, 268, 10.1016/j.pupt.2010.02.001 · DOI
  58. Harbeson, 2017, Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development, J. Pharmacol. Exp. Ther., 362, 359, 10.1124/jpet.117.241497 · DOI
  59. Jensen, 1995, Multiple proteolytic systems, including the proteasome, contribute to CFTR processing, Cell, 83, 129, 10.1016/0092-8674(95)90241-4 · DOI
  60. Strub, M.D., and McCray, P.B. (2020). Transcriptomic and Proteostasis Networks of Cftr and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. Genes, 11. · DOI
  61. Yang, 2003, Nanomolar Affinity Small Molecule Correctors of Defective Delta F508-Cftr Chloride Channel Gating, J. Biol. Chem., 278, 35079, 10.1074/jbc.M303098200 · DOI
  62. Clancy, 2012, Results of a Phase Iia Study of Vx-809, an Investigational Cftr Corrector Compound, in Subjects with Cystic Fibrosis Homozygous for the F508del-Cftr Mutation, Thorax, 67, 12, 10.1136/thoraxjnl-2011-200393 · DOI
  63. Boyle, 2014, A Cftr Corrector (Lumacaftor) and a Cftr Potentiator (Ivacaftor) for Treatment of Patients with Cystic Fibrosis Who Have a Phe508del Cftr Mutation: A Phase 2 Randomised Controlled Trial, Lancet Respir. Med., 2, 527, 10.1016/S2213-2600(14)70132-8 · DOI
  64. Wainwright, 2015, Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, N. Engl. J. Med., 373, 220, 10.1056/NEJMoa1409547 · DOI · Paper page
  65. Konstan, 2017, Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): A phase 3, extension study, Lancet Respir. Med., 5, 107, 10.1016/S2213-2600(16)30427-1 · DOI · Paper page
  66. Dagenais, R.V.E., Su, V.C.H., and Quon, B.S. (2020). Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J. Clin. Med., 10. · DOI
  67. Guevara, 2017, The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis, Expert Opin. Drug Saf., 16, 1305, 10.1080/14740338.2017.1372419 · DOI
  68. Veit, 2014, Some Gating Potentiators, Including Vx-770, Diminish Deltaf508-Cftr Functional Expression, Sci. Transl. Med., 6, 246ra97, 10.1126/scitranslmed.3008889 · DOI · Paper page
  69. Donaldson, 2018, Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR, Am. J. Respir. Crit. Care Med., 197, 214, 10.1164/rccm.201704-0717OC · DOI
  70. Schneider, 2018, Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor, Drug Metab. Lett., 12, 71, 10.2174/1872312812666180328105259 · DOI
  71. Munck, 2020, Tezacaftor/Ivacaftor in People with Cystic Fibrosis Heterozygous for Minimal Function Cftr Mutations, J. Cyst. Fibros., 19, 962, 10.1016/j.jcf.2020.04.015 · DOI · Paper page
  72. McKone, 2021, A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation, J. Cyst. Fibros., 20, 234, 10.1016/j.jcf.2020.11.003 · DOI
  73. Munck, 2017, Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del, N. Engl. J. Med., 377, 2013, 10.1056/NEJMoa1709846 · DOI · Paper page
  74. Rowe, 2017, Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis, N. Engl. J. Med., 377, 2024, 10.1056/NEJMoa1709847 · DOI · Paper page
  75. Schwarz, 2021, Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events, J. Cyst. Fibros., 20, 228, 10.1016/j.jcf.2020.06.001 · DOI
  76. Walker, 2019, A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis, J. Cyst. Fibros., 18, 708, 10.1016/j.jcf.2019.06.009 · DOI
  77. Davies, 2021, A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation, J. Cyst. Fibros., 20, 68, 10.1016/j.jcf.2020.07.023 · DOI
  78. Okiyoneda, 2013, Simon, A.; et al. Mechanism-Based Corrector Combination Restores Deltaf508-Cftr Folding and Function, Nat. Chem. Biol., 9, 444, 10.1038/nchembio.1253 · DOI · Paper page
  79. Holmes, 2014, False dawn for cystic fibrosis disease modifiers?, Nat. Rev. Drug Discov., 13, 713, 10.1038/nrd4456 · DOI
  80. Rowe, 2016, Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR, Ann. Am. Thorac. Soc., 14, 213, 10.1513/AnnalsATS.201609-689OC · DOI · Paper page
  81. Keating, 2018, VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med., 379, 1612, 10.1056/NEJMoa1807120 · DOI · Paper page
  82. Davies, 2018, VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med., 379, 1599, 10.1056/NEJMoa1807119 · DOI · Paper page
  83. Safirstein, 2021, Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis, J. Cyst. Fibros., 20, 506, 10.1016/j.jcf.2020.07.014 · DOI
  84. Rotolo, 2020, Testicular Pain Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Males with Cystic Fibrosis, J. Cyst. Fibros., 19, e39, 10.1016/j.jcf.2020.04.017 · DOI
  85. Goodwin, 2021, Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series, J. Cyst. Fibros., 20, 399, 10.1016/j.jcf.2020.12.011 · DOI
  86. Song, 2021, Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis, J. Cyst. Fibros., 20, e19, 10.1016/j.jcf.2020.07.016 · DOI
  87. Zemanick, E.T., Taylor-Cousar, J.L., Davies, J., Gibson, R.L., Mall, M., McKone, E.F., McNally, P., Ramsey, B.W., Rayment, J.H., and Rowe, S.M. (2021). A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 through 11 Years of Age with CF and at Least One F508del Allele. Am. J. Respir. Crit. Care Med. · DOI · Paper page
  88. Carroll, 2021, Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease, Eur. Respir. J., 57, 2003079, 10.1183/13993003.03079-2020 · DOI
  89. Burgel, P.R., Durieu, I., Chiron, R., Ramel, S., Danner-Boucher, I., Prevotat, A., Grenet, D., Marguet, C., Reynaud-Gaubert, M., and Macey, J. (2021). Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am. J. Respir. Crit. Care Med. · DOI
  90. DiMango, 2021, Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis, J. Cyst. Fibros., 20, 460, 10.1016/j.jcf.2020.07.002 · DOI
  91. Veit, G., Vaccarin, C., and Lukacs, G.L. (2021). Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J. Cyst. Fibros. · DOI
  92. Cuyx, 2019, Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis, Semin. Respir. Crit. Care Med., 40, 762, 10.1055/s-0039-1696664 · DOI
  93. Zemanick, E.T., Konstan, M.W., VanDevanter, D.R., Rowe, S.M., Clancy, J., Odem-Davis, K., Skalland, M., and Mayer-Hamblett, N. (2021). Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J. Cyst. Fibros. · DOI
  94. Eckford, 2019, The Cf Canada-Sick Kids Program in Individual Cf Therapy: A Resource for the Advancement of Personalized Medicine in Cf, J. Cyst. Fibros., 18, 35, 10.1016/j.jcf.2018.03.013 · DOI
  95. Dekkers, 2013, A functional CFTR assay using primary cystic fibrosis intestinal organoids, Nat. Med., 19, 939, 10.1038/nm.3201 · DOI · Paper page
  96. Amaral, 2019, Theranostics by Testing Cftr Modulators in Patient-Derived Materials: The Current Status and a Proposal for Subjects with Rare Cftr Mutations, J. Cyst. Fibros., 18, 685, 10.1016/j.jcf.2019.06.010 · DOI
  97. Groot, 2020, Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations, J. Cyst. Fibros., 19, 614, 10.1016/j.jcf.2019.10.022 · DOI
  98. Silva, 2020, Organoids as a Personalized Medicine Tool for Ultra-Rare Mutations in Cystic Fibrosis: The Case of S955p and 1717-2a>G, Biochim. Biophys. Acta Mol. Basis Dis., 1866, 165905, 10.1016/j.bbadis.2020.165905 · DOI
  99. Molinski, 2017, Orkambi(R) and Amplifier Co-Therapy Improves Function from a Rare Cftr Mutation in Gene-Edited Cells and Patient Tissue, EMBO Mol. Med., 9, 1224, 10.15252/emmm.201607137 · DOI
  100. Flume, 2018, WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis, J. Cyst. Fibros., 17, S1, 10.1016/S1569-1993(18)30120-6 · DOI
  101. Wilschanski, 2003, Gentamicin-Induced Correction of Cftr Function in Patients with Cystic Fibrosis and Cftr Stop Mutations, N. Engl. J. Med., 349, 1433, 10.1056/NEJMoa022170 · DOI
  102. Aksit, 2019, Decreased mRNA and protein stability of W1282X limits response to modulator therapy, J. Cyst. Fibros., 18, 606, 10.1016/j.jcf.2019.02.009 · DOI
  103. Keenan, 2019, Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR, Am. J. Respir. Cell Mol. Biol., 61, 290, 10.1165/rcmb.2018-0316OC · DOI
  104. Kerem, 2014, Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial, Lancet Respir. Med., 2, 539, 10.1016/S2213-2600(14)70100-6 · DOI
  105. Crawford, 2021, Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids, J. Cyst. Fibros., 20, 436, 10.1016/j.jcf.2021.01.009 · DOI
  106. Alroy, 2018, Translational Read-through of Ctns Nonsense Mutation and Attenuation F Ctns Nonsense-Mediated Mrna Decay by Elx-02 Treatment, Mol. Genet. Metab., 123, S18, 10.1016/j.ymgme.2017.12.020 · DOI
  107. Mutyam, 2021, Novel Correctors and Potentiators Enhance Functional Rescue of Cftr Nonsense Mutation Translational Readthrough, Am. J. Respir. Cell Mol. Biol., 64, 604, 10.1165/rcmb.2019-0291OC · DOI
  108. Okiyoneda, 2011, Protein quality control at the plasma membrane, Curr. Opin. Cell Biol., 23, 483, 10.1016/j.ceb.2011.04.012 · DOI
  109. Moniz, 2012, HGF Stimulation of Rac1 Signaling Enhances Pharmacological Correction of the Most Prevalent Cystic Fibrosis Mutant F508del-CFTR, ACS Chem. Biol., 8, 432, 10.1021/cb300484r · DOI
  110. Alshafie, 2014, Vip Regulates Cftr Membrane Expression and Function in Calu-3 Cells by Increasing Its Interaction with Nherf1 and P-Erm in a Vpac1- and Pkcepsilon-Dependent Manner, Am. J. Physiol. Cell Physiol., 307, C107, 10.1152/ajpcell.00296.2013 · DOI
  111. Marozkina, 2010, Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy, Proc. Natl. Acad. Sci. USA, 107, 11393, 10.1073/pnas.0909128107 · DOI
  112. Donaldson, 2017, Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR, J. Cyst. Fibros., 16, 371, 10.1016/j.jcf.2017.01.009 · DOI
  113. Robinson, 2018, Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis, Mol. Ther., 26, 2034, 10.1016/j.ymthe.2018.05.014 · DOI · Paper page
  114. Cooney, 2019, A Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs, Am. J. Respir. Cell Mol. Biol., 61, 747, 10.1165/rcmb.2019-0006OC · DOI
  115. Brommel, 2020, Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease, Hum. Gene Ther., 31, 985, 10.1089/hum.2020.138 · DOI
  116. Breunig, C.T., Durovic, T., Neuner, A.M., Baumann, V., Wiesbeck, M.F., Köferle, A., Götz, M., Ninkovic, J., and Stricker, S.H. (2018). One step generation of customizable gRNA vectors for multiplex CRISPR approaches through string assembly gRNA cloning (STAgR). PLoS ONE, 13. · DOI
  117. Zhou, 2019, In Vitro Validation of a CRISPR-Mediated CFTR Correction Strategy for Preclinical Translation in Pigs, Hum. Gene Ther., 30, 1101, 10.1089/hum.2019.074 · DOI
  118. Mall, 1998, The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways, J. Clin. Investig., 102, 15, 10.1172/JCI2729 · DOI
  119. Stutts, 1995, Cftr as a Camp-Dependent Regulator of Sodium Channels, Science, 269, 847, 10.1126/science.7543698 · DOI
  120. Mall, 2004, Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice, Nat. Med., 10, 487, 10.1038/nm1028 · DOI
  121. Mall, 2020, ENaC inhibition in cystic fibrosis: Potential role in the new era of CFTR modulator therapies, Eur. Respir. J., 56, 2000946, 10.1183/13993003.00946-2020 · DOI
  122. Nickolaus, P., Jung, B., Sabater, J., Constant, S., and Gupta, A. (2020). Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis. ERJ Open Res., 6. · DOI
  123. Goss, C.H., Jain, R., Seibold, W., Picard, A.C., Hsu, M.C., Gupta, A., and Fajac, I. (2020). An Innovative Phase Ii Trial to Establish Proof of Efficacy and Optimal Dose of a New Inhaled Epithelial Sodium Channel Inhibitor Bi 1265162 in Adults and Adolescents with Cystic Fibrosis: Balance-Cf™ 1. ERJ Open Res., 6. · DOI
  124. Danahay, H., and Gosling, M. (2020). TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?. Int. J. Mol. Sci., 21. · DOI
  125. Yerxa, 2002, Pharmacology of INS37217 [P1-(Uridine 5′)-P4- (2′-deoxycytidine 5′)tetraphosphate, Tetrasodium Salt], a Next-Generation P2Y2 Receptor Agonist for the Treatment of Cystic Fibrosis, J. Pharmacol. Exp. Ther., 302, 871, 10.1124/jpet.102.035485 · DOI
  126. Zeitlin, 2004, A Phase I Trial of Intranasal Moli1901 for Cystic Fibrosis, Chest, 125, 143, 10.1378/chest.125.1.143 · DOI
  127. Accurso, 2011, Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function, Am. J. Respir. Crit. Care Med., 183, 627, 10.1164/rccm.201008-1267OC · DOI
  128. Ratjen, 2012, Long term effects of denufosol tetrasodium in patients with cystic fibrosis, J. Cyst. Fibros., 11, 539, 10.1016/j.jcf.2012.05.003 · DOI
  129. Grasemann, 2007, Inhalation of Moli1901 in Patients With Cystic Fibrosis, Chest, 131, 1461, 10.1378/chest.06-2085 · DOI
  130. Danahay, 2020, TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis, Am. J. Respir. Crit. Care Med., 201, 946, 10.1164/rccm.201908-1641OC · DOI
  131. Danahay, 2020, Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks, Am. J. Respir. Crit. Care Med., 202, 905, 10.1164/rccm.202004-1214LE · DOI
  132. Muraglia, 2019, Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia, Nat. Cell Biol., 567, 405
  133. Chorghade, 2021, Amphotericin B induces epithelial voltage responses in people with cystic fibrosis, J. Cyst. Fibros., 20, 540, 10.1016/j.jcf.2020.11.018 · DOI
  134. Li, 2016, Efficient, Non-Toxic Anion Transport by Synthetic Carriers in Cells and Epithelia, Nat. Chem., 8, 24, 10.1038/nchem.2384 · DOI
  135. Hernando, 2018, Small Molecule Anionophores Promote Transmembrane Anion Permeation Matching Cftr Activity, Sci. Rep., 8, 2608, 10.1038/s41598-018-20708-3 · DOI
  136. Cossu, 2018, Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy, Front. Pharmacol., 9, 852, 10.3389/fphar.2018.00852 · DOI
  137. Fiore, 2019, Small molecule-facilitated anion transporters in cells for a novel therapeutic approach to cystic fibrosis, Br. J. Pharmacol., 176, 1764, 10.1111/bph.14649 · DOI
  138. Gianotti, A., Capurro, V., Delpiano, L., Mielczarek, M., García-Valverde, M., Carreira-Barral, I., Ludovico, A., Fiore, M., Baroni, D., and Moran, O. (2020). Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia. Int. J. Mol. Sci., 21. · DOI
  139. Crooke, 2017, Molecular Mechanisms of Antisense Oligonucleotides, Nucleic Acid Ther., 27, 70, 10.1089/nat.2016.0656 · DOI
  140. Wu, 2004, Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs, J. Biol. Chem., 279, 17181, 10.1074/jbc.M311683200 · DOI
  141. Crosby, 2017, Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice, J. Cyst. Fibros., 16, 671, 10.1016/j.jcf.2017.05.003 · DOI
  142. Michaels, 2020, Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells, Nucleic Acids Res., 48, 7454
  143. Mayer-Hamblett, N., Nichols, D.P., Odem-Davis, K., A Riekert, K., Sawicki, G.S., Donaldson, S.H., Ratjen, F., Konstan, M.W., Simon, N., and Rosenbluth, D.B. (2021). Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Study Design. Ann. Am. Thorac. Soc. · DOI

Cited by

Sorted by citations

Metadata

Authors
Bergeron, C., & Cantin, A. M.
Affiliations
Department of Medicine, Respiratory Division, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
ORCID
Bergeron, Christelle
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-06-08
Volume
22
Issue
12
Pages
6193
ISSN
1422-0067
DOI
10.3390/ijms22126193
PMC
PMC8227161
Cited by
22
References
10
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review